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Effect of carvedilol on adenylate cyclase activity in erythrocyte
membranes in patients with chronic heart failure
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OBJECTIVES The aim of the study was to evaluate the effect of car-
vedilol on adenylyl cyclase (AC) activity in erythrocyte membranes in
patients with chronic heart failure (CHF).
METHODS There were studied 56 patients aged from 45 to 55 (mean
age 51.24.6 years) years with CHF FCII-III. All the patients were
divided into two groups according to the New York Heart Classiﬁca-
tion (NYHA) functional class (FC). NYHA FC was determined by the 6-
minute walk test (6MWT) and the Russian scale of evaluation of the
clinical condition of the patients (V.Yu. Mareev, 2000). All patients
underwent clinical examination, ECG, and echocardiography. Group
1 consisted of 30 post-MI patients with CHF FC-II and Group 2 con-
sisted of 26 post-MI patients with CHF-III. The AC activity in red
blood cells homogenate was determined according to the method of
Y. Salomon. All patients received a carvedilol, nonselective beta
blocker with a1-, b1- and b2- blocking properties, on the background
of basic therapy (ACE inhibitors, spironolactone, nitrates, aspirin,
loop diuretics). Initial carvedilol dosage was 3.125 mg and was
titrated to achieve the target dosage of 25–50 mg twice a day.
Mean carvedilol dosage was 23.84.6 mg/day in Group 1 and
33.656.9 mg/day in Group II. Results were statistically processed
using the software package Statistica 6.1 for Windows and the Excel
package of Microsoft Excel 2007. The mean (M) and Standard Devi-
ation (SD) were deduced.
RESULTS Basal AC activity was less by 31.9% in patients of Group 1
compared to the control group (4.150.14 vs 6.10.19 pmol/mg/min);
in patients of Group 2 it was less by 41.6% compared to the control
group (3.560.13 vs 6.10.19 pmol/mg/min) and by 14.2% compared to
Group 1 patients. In the control group, we found an increase in the
epinephrine-stimulated AC activity of about 2 times in comparison
with basal level (11.30.5 vs 6.10.19 pmol/mg/min, P<0.01). In Group
1 patients, the epinephrine-stimulated AC activity was lower about 2
times compared to the control group (5.50.19 pmol/mg/min vs.
11.30.5 pmol/mg /min). In Group 2 patients, this parameter was
reduced to 3.850.19 pmol/mg/min and was 65.9% (P <0.05) lower
than in the control group and 28.7% lower than in Group1 patients.
Long-term therapy with carvedilol (for 6 months) was accompanied by
an increase in AC activity by 15.3% in patients with CHF FC-II and
13.9% in patients with CHF FC-III in comparison with the initial data
(P <0.05).
CONCLUSIONS In patients with CHF FC I-III, there was a reduction
of adenylate cyclase activity, which is more pronounced in patients
in group 2 and therapy with carvedilol for 6 months increases
the AC activity in erythrocyte membranes in patients with CHF
FCII-III.
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Analyses of risk factors for heart failure and cardiac mortality after surgical
operation of proximal femoral fractures
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OBJECTIVES Patients undergoing surgical operation of proximal
femoral fracture are at risk for heart failure and cardiac mortality. The
objective of this work is to identify predictors of heart failure and
cardiac mortality and in-hospital death in surgical patients of prox-
imal femoral fracture.
METHODS From the Surgery of proximal femoral fracture Registry
(2,238 operations from January 2003 through December 2013), it was
identiﬁed that 28 patients in whom heart failure developed during the
same hospital stay. The data were analyzed regarding preoperative
cardiac disease and surgical and anesthetic factors to study associa-
tion with heart failure and cardiac death according to the type of
surgery, gender, patient age, and year of surgery.
RESULTS By using univariable analysis the following predictors of
heart failure were identiﬁed: valvular disease (P ¼ 0.04), general
anesthesia (P ¼ 0.03), preoperative history of coronary artery disease
(P ¼ 0.001), preoperative treatment with beta-blockers (P ¼ 0.003),
lower preoperative (P ¼ 0.03) and postoperative (P ¼ 0.002)hemoglobin concentrations, increased bleeding rate (P ¼ 0.025). Of
the 28 patients with heart failure, 21.4% died of cardiac cause during
the same hospital stay. The following factors increased the odds ratios
for cardiac death: age (P ¼ 0.001), type of surgery (P ¼ 0.05), lower
intraoperative diastolic blood pressure (P ¼ 0.001), new intraoperative
ST-T changes (P ¼ 0.01). Patients who underwent coronary artery
bypass grafting, even more than 12 months before index surgery, had
a 56% reduction in risk of death if they had perioperative myocardial
infarction (P ¼ 0.01). Multivariable analysis revealed preoperative
deﬁnitive diagnosis of coronary artery disease (P ¼ 0.001) and sig-
niﬁcant valvular disease (P ¼ 0.04) were associated with increased
risk of heart failure. Increased intraoperative use of blood (P ¼ 0.005)
were associated with cardiac death.
CONCLUSIONS The in-hospital cardiac mortality rate is high for pa-
tients of proximal femoral fracture who undergo surgery and experi-
ence clinically signiﬁcant heart failure. Stress of surgery (increased
intraoperative bleeding), poor preoperative cardiac functional status
(lower ejection fraction, diagnosis of coronary artery disease) are the
factors that determine perioperative cardiac morbidity and mortality
rates.GW26-e2330
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OBJECTIVES To evaluate the efﬁcacy and safety of 1-h infusion of
recombinant human atrial natriuretic peptide (rhANP), in combination
with standard therapy, in patients with acute decompensated heart
failure (ADHF).
METHODS Eligible patients with ADHF were randomized to receive
either rhANP or placebo for 1-hr infusion at a ratio of 3:1 in combi-
nation with standard therapy. The primary endpoint was dyspnoea
improvement (a decrease of at least two grades of severity in dysp-
noea at 12 h from baseline). In addition, reduction in pulmonary
capillary wedge pressure (PCWP) one 1 h after infusion was the co-
primary endpoint for catheterized patients.
RESULTS Overall, 477 patients were randomized into two groups: 358
(93 catheterized) patients with rhANP and 118 (28 catheterized) with
placebo. The proportion of patients with dyspnoea improvement at 12
h was higher, although not statistically signiﬁcant, in the rhANP group
than in the placebo group (32.0% vs. 25.4%, odds ratio¼1.382, 95%
conﬁdence interval: 0.863-2.212, P ¼0.172). Reduction in PCWP at 1 h
was signiﬁcantly greater in patients treated with rhANP than those
with placebo (-7.745.95 vs. -1.824.47 mmHg, P <0.001). The fre-
quencies of adverse events and renal impairment within 3 days were
similar between the two groups. Serious adverse events and mortality
at 1month were low in both groups.
CONCLUSIONS For ADHF patients receiving standard therapy, 1-h
rhANP infusion results in prompt, transient hemodynamic improve-
ment with a small, but non-signiﬁcant, effect on dyspnoea. The safety
of 1-h rhANP infusion is acceptable. (WHO International Clinical Trials
Registry Platform (ICTRP) number, ChiCTR-IPR-14005719.)
